Back

Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study

20 May 2025 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Interventions to improve outcomes in cardio-oncology Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Isabel Martins Moreira

Hospital Center of Tras-os-Montes and Alto Douro, Vila Real (Portugal)

4 More presentations in this session

Presentation thumbnail
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors
Doctor M. Slieman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
Doctor I. Araujo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Cardiotoxicity and immune checkpoint inhibitors: a heartfelt myth or the real deal?
Doctor S. Esteves (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Interventions to improve outcomes in cardio-oncology

The Event

Event poster

Heart Failure 2025

20 May 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Treatment options for cancer therapy-related cardiac dysfunction
thumbnail
Congress Presentation
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources